• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Up0.25% Nasdaq Up0.65%

    MetaStat, Inc. (MTST)

    -Other OTC
    2.15 Down 0.04(1.83%) May 27, 9:30AM EDT
    ProfileGet Profile for:
    MetaStat, Inc.
    27 Drydock Avenue
    2nd Floor
    Boston, MA 02210-2377
    United States - Map
    Phone: 617-531-6500
    Website: http://www.metastat.com

    Index Membership:N/A
    Full Time Employees:5

    Business Summary 

    MetaStat, Inc., a molecular diagnostic company, focuses on developing and commercializing epigenetic-based diagnostic tests for the prediction of systemic metastasis. The company’s MetaSite Breast and MenaCalc diagnostic product candidates are designed to stratify patients based on their individual risk of metastasis and to allow oncologists to customize cancer treatment decisions by identifying patients with high-risk of metastasis who need aggressive therapy and by sparing patients with low-risk of metastasis from the harmful side effects and expense of chemotherapy. Its MetaSite Breast test is applicable for early stage breast cancer patients; and MenaCalc test is a platform applicable to various epithelial-based cancers, including breast, prostate, lung, and colorectal. Metastat, Inc. is based in Boston, Massachusetts.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on MetaStat, Inc.

    Key Executives 
    Mr. Daniel H. Schneiderman , 38
    VP of Fin. and Sec.
    Mr. Douglas A. Hamilton B.Sc., MBA, 50
    Chief Exec. Officer and Pres
    Mr. Frederick E. Pierce II,
    VP of Investor Relations
    Dr. Michael J. Donovan Ph.D., M.D.,
    Acting Chief Medical Officer
    Mr. Anthony P. Shuber , 57
    Head of Diagnostic R&D
    Amounts are as of Dec 31, 2015 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders